Understanding how a specific enzyme affects cancer spread
Elucidating pro-metastatic collagen modifying activities of lysyl hydroxylase 2
This study is looking at how a specific enzyme called LH2 helps cancer cells spread by making the surrounding tissue stiffer, which could lead to new ways to treat cancer and improve patient care.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-11056804 on NIH RePORTER |
What this research studies
This research investigates the role of lysyl hydroxylase 2 (LH2), an enzyme that modifies collagen, in the spread of cancer cells. By studying how LH2 contributes to the formation of stable collagen cross-links that enhance tumor stiffness, the research aims to uncover mechanisms that allow cancer cells to invade surrounding tissues. The approach includes analyzing the structural properties of LH2 and its interactions with collagen, which could lead to new insights into cancer metastasis. Patients may benefit from a deeper understanding of how their tumors spread, potentially leading to targeted therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with metastatic cancers, particularly lung cancer, who may benefit from targeted therapies aimed at collagen modification.
Not a fit: Patients with non-metastatic cancers or those whose tumors do not involve collagen modification may not receive benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that inhibit cancer metastasis, improving patient outcomes.
How similar studies have performed: Other research has shown promising results in targeting collagen modification to inhibit cancer progression, suggesting that this approach may be effective.
Where this research is happening
Houston, United States
- University of Tx Md Anderson Can Ctr — Houston, United States (Active)
Researchers
- Principal investigator: Kurie, Jonathan M — University of Tx Md Anderson Can Ctr
- Study coordinator: Kurie, Jonathan M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.